A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors

Oncology

Volumn 61, Issue 4, 2001, Pages 265-270

  Kakolyris, Stelios ^a   Kouroussis, Ch ^a   Souglakos, J ^a   Mavroudis, D ^a   Agelaki, S ^a   Kalbakis, K ^a   Androulakis, N ^a   Vardakis, N ^a   Vamvakas, L ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Phase I; Solid tumors; Topotecan

Indexed keywords

CYTOTOXIC AGENT; DNA TOPOISOMERASE; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MELANOMA; NEUTROPENIA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; OVARIAN NEOPLASMS; THROMBOCYTOPENIA; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 17944372197     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055332     Document Type: Article

References (16)

1. Topoisomerase I inhibitors: Topotecan and irinotecan
2. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
3. Clinical trials with topoisomerase I inhibitors
4. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen
5. Phase I and pharmacokinetic study of topotecan: A novel topoisomerase I inhibitor
6. Camptothecins
7. Phase I clinical and pharmacologic study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempts at dose intensification using recombinant granulocyte colony stimulating factors
8. Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor
9. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
10. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
11. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial
12. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
13. Phase II study of topotecan in patients with extensive stage small cell lung cancer: An Eastern Cooperative Oncology Group Trial
14. Topotecan, a new active drug in the second-line treatment of small cell lung cancer: A phase II study in patients with refractory and sensitive disease
15. Treatment of patients with small cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison, topotecan